Sebastian Nijman

Biotech Park — India

Biochemistry, Genetics and Molecular Biology · Life Sciences

30h-index9.6kcitations105works1.02yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Microtubule and mitosis dynamics(25), Neuroblastoma Research and Treatments(24), Cancer, Hypoxia, and Metabolism(23), HIV/AIDS drug development and treatment(18), CRISPR and Genetic Engineering(14)

Publications105 total

Genetic suppression features ABHD18 as a Barth syndrome therapeutic target

4 cited

Nature·2025· 4 cited

PLA2G15 is a BMP hydrolase and its targeting ameliorates lysosomal disease

16 cited

Nature·2025· 16 citedOpen Access

Table S2 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

2024Open Access

Supplementary Figure 2 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

2024Open Access

Supplementary Figure 3 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

2024Open Access

Supplementary Figure 4 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

2024Open Access

Figure 2 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

2024Open Access

Figure 6 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

2024Open Access

Figure 1 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

2024Open Access

Table S1 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

2024Open Access

Supplementary Figure 6 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

2024Open Access

Supplementary Figure 5 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

2024Open Access

Figure 5 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

2024Open Access

Supplementary Materials from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

2024Open Access

Supplementary Figure 2E from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

2024Open Access

Supplementary Figure 1 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

2024Open Access

Table S3 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

2024Open Access

Data from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

2024Open Access

Figure 3 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

2024Open Access

Figure 4 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

2024Open Access

page 1 of 6Next →

Frequent Co-authors

Thijn R. Brummelkamp(11), Markus K. Muellner(10), Tomasz Konopka(8), Claudia Kerzendorfer(8), René Bernards(7), Bianca V. Gapp(7), Jacques Colinge(7), Barbara Mair(6), Erica De Zan(6), Annette M.G. Dirac(5), Iris Z. Uras(5), Giulio Superti‐Furga(5), Stefan Kubicek(5), Hagen Schwenzer(5), Mustafa Elshani(5), Ruud van Stiphout(5), Mary Kudsy(5), Josephine Morris(5), Valentina Ferrari(5), James Chettle(5)